CannBioRx Life Sciences Corp
180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases in the United States. The company product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed phase 2a and phase 2b proof-of-concept clinical t… Read more
CannBioRx Life Sciences Corp (ATNFW) - Net Assets
Latest net assets as of June 2025: $5.38 Million USD
Based on the latest financial reports, CannBioRx Life Sciences Corp (ATNFW) has net assets worth $5.38 Million USD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($10.71 Million) and total liabilities ($5.33 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $5.38 Million |
| % of Total Assets | 50.22% |
| Annual Growth Rate | 112.94% |
| 5-Year Change | -69.45% |
| 10-Year Change | N/A |
| Growth Volatility | 180337.46 |
CannBioRx Life Sciences Corp - Net Assets Trend (2016–2024)
This chart illustrates how CannBioRx Life Sciences Corp's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for CannBioRx Life Sciences Corp (2016–2024)
The table below shows the annual net assets of CannBioRx Life Sciences Corp from 2016 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $9.25 Million | +7343.16% |
| 2023-12-31 | $-127.73K | -101.13% |
| 2022-12-31 | $11.34 Million | -71.15% |
| 2021-12-31 | $39.32 Million | +29.83% |
| 2020-12-31 | $30.29 Million | -21.48% |
| 2019-12-31 | $38.57 Million | -66.13% |
| 2018-12-31 | $113.87 Million | +0.92% |
| 2017-12-31 | $112.83 Million | +515319.02% |
| 2016-12-31 | $21.89K | -- |
Equity Component Analysis
This analysis shows how different components contribute to CannBioRx Life Sciences Corp's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 14152023400.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $318.00 | 0.00% |
| Other Comprehensive Income | $-2.92 Million | -31.53% |
| Other Components | $153.69 Million | 1661.19% |
| Total Equity | $9.25 Million | 100.00% |
CannBioRx Life Sciences Corp Competitors by Market Cap
The table below lists competitors of CannBioRx Life Sciences Corp ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
ROYAL GOLD (RG3.SG)
STU:RG3
|
$2.17 Million |
|
Nova Organic PCL
BK:NV
|
$2.17 Million |
|
C29 Metals Ltd
AU:C29
|
$2.17 Million |
|
Guided Therapeutics Inc
OTCQB:GTHP
|
$2.17 Million |
|
DSV AS
BE:DS81
|
$2.17 Million |
|
Auric Resources Corp.
V:RES
|
$2.17 Million |
|
Interactive Strength Inc. Common Stock
NASDAQ:TRNR
|
$2.17 Million |
|
Armory Mining Corp.
PINK:RMRYF
|
$2.17 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in CannBioRx Life Sciences Corp's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -127,733 to 9,251,911, a change of 9,379,644.
- Net loss of 6,168,000 reduced equity.
- Dividend payments of 8,011,510 reduced retained earnings.
- New share issuances of 2,572,789 increased equity.
- Other comprehensive income decreased equity by 15,579.
- Other factors increased equity by 21,001,944.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-6.17 Million | -66.67% |
| Dividends Paid | $8.01 Million | -86.59% |
| Share Issuances | $2.57 Million | +27.81% |
| Other Comprehensive Income | $-15.58K | -0.17% |
| Other Changes | $21.00 Million | +227.0% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares CannBioRx Life Sciences Corp's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.04x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 0.81x to 0.04x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | $0.53 | $0.43 | x |
| 2018-12-31 | $0.34 | $0.43 | x |
| 2019-12-31 | $9.13 | $0.43 | x |
| 2020-12-31 | $1.16 | $0.43 | x |
| 2021-12-31 | $4.77 | $0.43 | x |
| 2022-12-31 | $0.58 | $0.43 | x |
| 2023-12-31 | $-0.34 | $0.43 | x |
| 2024-12-31 | $10.11 | $0.43 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently CannBioRx Life Sciences Corp utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -66.67%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.38x
- Recent ROE (-66.67%) is above the historical average (-43674491.78%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | -14.20% | 0.00% | 0.00x | 10.96x | $-5.30K |
| 2017 | 2.48% | 0.00% | 0.00x | 23.41x | $-376.24K |
| 2018 | 20.82% | 0.00% | 0.00x | 23.69x | $541.00K |
| 2019 | -65.84% | 0.00% | 0.00x | 1.35x | $-29.25 Million |
| 2020 | -35.94% | 0.00% | 0.00x | 1.83x | $-13.91 Million |
| 2021 | -51686813.43% | 0.00% | 0.00x | 1.59x | $-20.32 Trillion |
| 2022 | -341383453.23% | 0.00% | 0.00x | 1.73x | $-38.73 Trillion |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | $-19.92 Million |
| 2024 | -66.67% | 0.00% | 0.00x | 1.38x | $-7.09 Million |
Industry Comparison
This section compares CannBioRx Life Sciences Corp's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| CannBioRx Life Sciences Corp (ATNFW) | $5.38 Million | -14.20% | 0.99x | $2.17 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |